Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TransPot

Financiado

Cerrado

Translational Research Network in Prostate Cancer

The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scien... ver más

30/04/2021

UNIVERSITY OF GLAS...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITY OF GLASGOW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-30

MSCA-ITN-2016: Innovative Training Networks

I+D

Cerrada hace 9 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

UNIVERSITY OF GLASGOW

273.29K€ | Lider

Prostate Cancer UK

N.D. | Participante

UNIVERSITY OF TURKU

269.15K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RESICT-PC Studying Resistance to Cancer Therapeutics in Prostate Cance... 231K€ Cerrado

PCaProTreat Multi omics molecular treatment targets for Prostate Cancer 171K€ Cerrado

PDX-PC Elucidation of tumour cell plasticity mechanisms associated... 166K€ Cerrado

STOPCa The cryptic path of tumor microenvironment interactions in p... 175K€ Cerrado

NOSCAR decipheriNg Oncogenic SIgnalling patterns to break CAncer dr... 305K€ Cerrado

SAF2011-28350 APLICACIONES DE LA RMN Y LA METABOLOMICA AL DESARROLLO DE NU... 230K€ Cerrado

Duración del proyecto: 56 meses Fecha Inicio: 2016-08-16
Fecha Fin: 2021-04-30

Líder del proyecto

UNIVERSITY OF GLASGOW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores